<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d26018_def14a.txt
<DESCRIPTION>DEFINITIVE PROXY STATEMENT
<TEXT>


                                DAXOR CORPORATION
                          350 Fifth Avenue, Suite 7120
                               New York, NY 10118



                    NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
                            TO BE HELD JUNE 21, 2001



     NOTICE IS HEREBY  GIVEN that the Annual  Meeting of  Shareholders  of DAXOR
CORPORATION  (the  "Company")  will  be  held at the  principal  offices  of the
Company, 350 Fifth Avenue (Empire State Building), Suite 7120, New York City, on
Thursday,  June 21, 2001 at 5:00 p.m.,  Eastern Standard Time, for the following
purposes:

     1. To elect a board of five directors, each to serve for a term of one year
and until his successor shall have been duly elected and qualified.

     2. To transact such other business as may properly come before the meeting,
or any adjournment thereof.

1.   Shareholders  of record at the close of  business  on May 16,  2001 will be
     entitled to notice of and to vote at the meeting.


                                          By Order of the Board of Directors,


                                          Virginia Fitzpatrick, Secretary


Dated:  May 16, 2001
New York, New York


IF YOU DO NOT EXPECT TO BE PRESENT AT THE MEETING AND WISH YOUR SHARES TO BE
VOTED, PLEASE DATE, SIGN, AND MAIL THE ACCOMPANYING FORM OF PROXY AS PROMPTLY AS
POSSIBLE IN THE ENCLOSED ENVELOPE.


                                       1
<PAGE>


                                DAXOR CORPORATION
                          350 Fifth Avenue, Suite 7120
                               New York, NY 10118



                                 PROXY STATEMENT


     The  accompanying  proxy is  solicited  by and on  behalf  of the  Board of
Directors of Daxor Corporation,  a New York Corporation (the "Company"), for use
at the Annual Meeting of Shareholders to be held at the principal offices of the
Company, 350 Fifth Avenue, Suite 7120, New York City, on Thursday, June 21, 2001
at 5:00 p.m., Eastern Standard Time (the "Meeting"), or any adjournment thereof.
Shareholders  of  record  at the  close of  business  on May 16,  2001,  will be
entitled to vote at the meeting.

     The Company will solicit  proxies by mail.  Arrangements  will be made with
brokerage  houses and other  custodians,  nominees,  and  fiduciaries to forward
solicitation  material to the beneficial  owners of the shares held of record by
such  persons,   and  the  Company  will   reimburse  them  for  the  reasonable
out-of-pocket expenses incurred by them in doing so.

     The shares  represented by the accompanying proxy will be voted as directed
with respect to the election of directors or, if no direction is indicated, will
be voted in favor of election as directors of the nominees  listed  below.  Each
proxy  executed  and  returned  by a  shareholder  may be  revoked  at any  time
hereafter by giving  written  notice of such  revocation to the Secretary of the
Company,  except  as to  any  matter  or  matters  upon  which,  prior  to  such
revocation,  a vote shall have been cast pursuant to the authority  conferred by
such proxy.

     The Annual Report to  Shareholders  for the fiscal year ended  December 31,
2000, including financial statements, is being sent to shareholders on or before
the date of this  Proxy  Statement  which is the  approximate  date on which the
Proxy Statement and form of Proxy are first being sent or given to shareholders.

     The Board of Directors of the Company,  on the  recommendation of its audit
committee  consisting of a majority of independent  directors,  has selected the
firm of Frederick  Kaden and Co. as the  principal  accountants  for the current
fiscal year.  They (and their  predecessors)  have served in such capacity since
1974.  Representatives of Frederick Kaden and Co. are not expected to be present
at the Meeting.


                                       2
<PAGE>


                  VOTING SECURITIES AND PRINCIPAL SHAREHOLDERS

     On May 16, 2001 the Company had issued and outstanding  4,664,909 shares of
common stock, par value $.01 per share ("Common Stock"),  each of which entitled
the holder to one vote. Voting is not cumulative.

     The following table sets forth information as of May 16, 2001, with respect
to all shareholders known by the Company to be beneficial owners of more than 5%
of the outstanding Common Shares, all Directors, and all Directors and executive
officers as a group. Except as noted below, each shareholder has sole voting and
investment power with respect to shares owned.

<TABLE>
<CAPTION>
                                                                    Number of
         Name & Address                                           Common Shares
         of Beneficial Owner                         Beneficially Owned         Percent
         -------------------                         ------------------         -------
<S>                                                       <C>                   <C>
Joseph Feldschuh, M.D. ........................           3,153,729             67.6%
President Daxor Corporation / Director
350 Fifth Avenue, Suite 7120
New York, NY 10118

Stephen M. Moss, Ph.D. / Director.......................        100**           *
P.O. Box 400
Bronxville, NY  10708-0400

James A. Lombard / Director .............................       200             **
190 East 206th Street
Bronx, NY  10458

Martin S. Wolpoff / Director............................      1,500**           *
5700 Arlington Avenue
Bronx, NY  10471

Bruce A. Hack / Director...................................   1,000**           *
113 Sunnyside Drive
Yonkers, NY. 10705

All Directors and executive officers as a group           3,156,529             67.7%
(8 Persons)
</TABLE>
* NOTE:  Less than 1%
**All Directors including the  President  have options for 1,000 shares of Daxor
     stock exercisable at $10.00/share

     Based on its review of copies of the forms  prescribed  by Section 16(a) of
the  Securities and Exchange  Commission  Act of 1934 or written  representation
from certain reporting persons that no Form 5's were required for those persons,
the Company believes that all of its Section 16 reporting  persons complied with
the filing requirements of Section 16(a) as of December 31, 2000.

                            I. Election of Directors

     An entire board of five  directors is proposed to be elected at the meeting
to hold office for a term of one year and until their successors shall have been
duly  elected  and shall  have  qualified.  The  proxies  will vote all  proxies
received  "FOR" the election as  directors  of the  nominees  listed below if no
direction to the  contrary is given.  In the event that any nominee is unable to
serve,  the proxy  solicited  herewith may be voted,  in the  discretion  of the
proxies, for the election of another person in his stead. The Board of Directors
knows of no reason to anticipate that this will occur.

     The  following  information  with  respect to current  and past five years'
business  experience,  age and directorship has been furnished to the Company as
of May 11, 2001, by each person nominated for election as director.


                                       3
<PAGE>

<TABLE>
<CAPTION>
                                            Principal Occupation                                 Director
                                            and Other Position                                   Continuously
Name                                        with the Company                                     Since
----                                        ----------------                                     -----

<S>                                         <C>                                                  <C>
Joseph Feldschuh, M.D., 65............      Chairman of the Board of Directors
                                            and President of the Company (1)                     1974
Stephen M. Moss, Ph.D., 48............      President, Toxophilus
                                            Risk Management Consulting (2)                       1986
James Lombard, 66.....................      Deputy Director of Administration
                                            City Council of the City of New York (3)             1989
Martin S. Wolpoff, 58.................      Director Information Services for the
                                            Division of Instructional Support(4)                 1989
Bruce A.Hack, 47......................      President, On-Line Power Technologies, Inc. (5)      1997
</TABLE>

----------
(1)  Joseph Feldschuh, M.D. has been President of Daxor since 1974. He is on the
     staff of Montefiore  Hospital and Medical  Center.  From 1966 to 1983,  Dr.
     Feldschuh was Director of the Cardiac Metabolic  Laboratory at Metropolitan
     Hospital.  He has been a Clinical Associate  Professor in both medicine and
     pathology at New York Medical College and an Assistant  Clinical  Professor
     at Cornell Medical  School.  He performed the basic research at the College
     of Physicians and Surgeons  (Columbia  University) on the  measurement  and
     prediction of normal human blood volume. He is the co-inventor of the Blood
     Volume Analyzer and the inventor of the quantitative  injection kit for the
     BVA-100. He is Board Certified in Cardiology and Internal Medicine.

(2)* Stephen M. Moss, Ph.D.  attended  Cambridge  University in England where he
     graduated  with First Class  Honors in  Mathematics  in 1975.  His graduate
     work,  also  at  Cambridge  University,  was in  the  field  of  Non-Linear
     Optimization,  and he received  Masters and  Doctoral  degrees in 1980.  He
     immigrated  to the  United  States in 1980,  and  worked for two years as a
     consultant  at  Bankers  Trust  Company  in New York.  From 1982 to 1992 at
     Lehman Brothers and successor firms he gained a wide range of experience in
     all major areas of investment banking and securities trading.  From 1992 to
     1993, he was the Chief  Information  Officer and a Senior Vice President at
     Republic New York Securities.  From 1993 to 1997, at American International
     Group,  a worldwide  insurance  and  financial  services  firm,  he was the
     Manager of Credit Risk  Management  Systems.  After  spending  two years at
     Salomon Smith Barney as the Director of Credit Risk Analytics,  he has just
     founded Toxophilus Risk Management Consulting. Dr. Moss is an active mentor
     in the Academy of Finance, an organization that provides pro bono financial
     services  training  and job  experience  to  students  in the New York City
     public schools.

(3)* James A. Lombard  graduated  from New York  University  Graduate  School of
     Business  Administration with an M.B.A. in Marketing,  Banking and Finance.
     He has been employed by the City Council of the City of New York since 1976
     and currently holds the position of Director, Counsel Services Division.

(4)* Martin S. Wolpoff holds  advanced  degrees from the City  University of New
     York - an M.A. in Social Studies and an M.S. in Educational  Administration
     and  Supervision.  He has been  actively  involved in community  activities
     since  the  1970's.  Some of the  groups  with  which he has been  involved
     include  serving  as a member,  and  three-year  chairperson,  on his local
     Community  Board;  member of a community  school board for nine years,  its
     president for three;  member of a Community  Development  Corporation;  and
     member of the community advisory board for a New York City hospital. He has
     been  employed by the New York City public  school  system since 1965 as an
     educator, supervisor and administrator. He is currently the Director.

(5)  Bruce A. Hack holds a B.E. in Electrical  Engineering  from City College in
     New York City. He is President of On-Line Power  Technologies Inc. Mr. Hack
     is a major Shareholder. Mr. Hack has 20 years experience in technical sales
     and  marketing  for  highly  engineered  products.  He  also  has  previous
     experience with major  worldwide  manufacturing  companies,  including such
     companies as Westinghouse Electrical Corporation and Siemens.

  * (member of the audit Committee)
There were five  meetings of the Board of Directors  during fiscal year 2000, of
which all were attended by all directors.


                                       4
<PAGE>

                                    OFFICERS

     DANIEL  J.  WELLINGTON   holds  an   undergraduate   degree  in  Mechanical
Engineering  from Clarkson  University and a MBA from the University of Phoenix.
His experience was with COBE Laboratories  (now Gambro,  Inc.) in Cardiovascular
R&D,  with  Biosurge,  Inc., as Vice  President of Technology  and just prior to
founding  Wellport He previously  worked with  Porterfield  Enterprises  as Vice
President of Engineering  Services.  He has distinguished  himself in nationally
recognized medical device design circles.  He was principally  involved with the
development  of a mechanical  intraoperative  autotransfer  device for Biosurge,
which was selected by R&D  magazine as one of the "Top 100" devices in 1990.  He
has a patent in the parallel  plate  oxygenator  subject  area.  In 1998,  Daxor
purchased the assets of Wellport  Corporation and Mr.  Wellington  became a Vice
President of Daxor.  He is  responsible  for the  Rochester  Division  where the
BVA-100 syringe is manufactured.  His  responsibilities  include compliance with
FDA regulatory matters.

     RONALD H. BALDRY was educated at the University of Durham in Great Britain,
where he received his  B.S.E.E.,  specializing  in electronic  instruments.  Mr.
Baldry was employed as a  development  engineer for  instrumentation  at nuclear
research  establishments  in  the  United  Kingdom  and at  Oak  Ridge  National
Laboratory.  Mr.  Baldry was involved in the original  mechanical  design of the
Company's  Blood  Volume  Analyzer  (BVA-100).  Mr.  Baldry was  appointed  Vice
President/Engineering in 1996. He heads Daxor Oak Ridge. He has been responsible
for  coordinating  construction  of the BVA-100.  His  responsibilities  include
coordination of other  sub-contractors  involved in the manufacturing of the BVA
system.

     OCTAVIA  ATANASIU  joined  Daxor  in May,  1994.  In  June,  1994,  she was
appointed to the position of Treasurer.  Ms. Atanasiu,  a graduate of University
of Romania,  Bucharest,  Romania,  she  received the  equivalent  of a Master of
Business Administration (MBA) with majors in Finance,  Accounting and Economics.
Prior to joining Daxor,  she was the Head of the Financial  Department of Marien
Business Forms, a printing corporation.

     VIRGINIA  FITZPATRICK  joined Daxor  Corporation in 1988, as Administrative
Assistant  to the  President.  Ms.  Fitzpatrick  was promoted to the position of
Corporate  Secretary in 1995. Since joining Daxor, Ms.  Fitzpatrick has been the
Liaison Coordinator for the Company's securities  portfolio.  She is responsible
for maintaining the Company's extensive data and research files.

                             EXECUTIVE COMPENSATION

     The following is the executive  compensation for officers earning more than
$100,000.00.

Dr. Joseph Feldschuh,  the Company's President,  CEO, & Chairman of the Board of
Directors:

               YEAR ENDED DEC. 31           SALARY            BENEFITS
               ------------------           ------            --------
                       2000                 $ 184,450                  $ 10,000
                       1999                 $ 195,000                  $ 10,000
                       1998                 $ 175,000                  $ 10,000

Ronald N. Baldry, the Company's Vice President/Engineering:

               YEAR ENDED DEC. 31           SALARY            BENEFITS
               ------------------           ------            --------
                       2000                 $ 182,744                   $1,500
                       1999                 $ 140,360.94                $1,500
                       1998                 $ 164,231.85                $1,500


                                       5
<PAGE>


For the year ended December  2000,  the Company paid Directors  $1,000 plus $300
for each meeting attended, plus expenses. The Company anticipates paying fees to
Directors up to a maximum of $2,500 per year to each non-employee director.

STOCK OPTIONS

     In 1994,  the Company  adopted a stock option plan under Section  422(b) of
the Internal  Revenue Code wherein  options  would be granted to key  employees,
officers and  directors  where the exercise  price would at least equal the fair
market value on the market  value on the date of grant.  The term of the options
are a maximum of five years.  At the present time there are options  outstanding
for 7,800 shares.

                               PERFORMANCE GRAPHS

                Comparison of Five-Year Cumulative Total Return*
 Daxor Corporation, Standard & Poors 500 And Value Line Medical Supplies Index
                     (Performance Results Through 12/31/00)

 [THE FOLLOWING TABLE WAS REPRESENTED BY A LINE GRAPH IN THE PRINTED MATERIAL]

                        1995      1996      1997      1998      1999      2000
                        ----      ----      ----      ----      ----      ----

Daxor Corporation      $100.00   $200.00   $201.70   $230.79   $224.97   $156.67
Standard & Poors 500   $100.00   $123.25   $164.21   $210.85   $253.61   $227.89
Medical Supplies       $100.00   $131.11   $190.52   $296.66   $326.44   $546.15

Assumes $100 invested at the close of trading 12/95 in Daxor Corporation  common
stock, Standard & Poors 500, and Medical Supplies.

* Cumulative total return assumes reinvestment of dividends.

                                                       Source:  Value Line, Inc.

Factual  material is obtained  from  sources  believed to be  reliable,  but the
publisher is not responsible for any errors or omissions contained herein.


                                       6
<PAGE>


Summary Data
Name                              1996      1997      1998      1999      2000
----                              ----      ----      ----      ----      ----

Daxor Corporation                 100.00      0.85     14.42     -2.52     30.36
Standard & Poors 500               23.25     33.24     28.40     20.28    -10.14
Medical Supplies                   31.11     45.31     55.71     10.04     67.31


Graph Plot Points
Name                     1995      1996      1997      1998      1999      2000
----                     ----      ----      ----      ----      ----      ----

Daxor Corporation       100.00    200.00    201.70    230.79    224.97    156.67
Standard & Poors 500    100.00    123.25    164.21    210.85    253.61    227.89
Medical Supplies        100.00    131.11    190.52    296.66    326.44    546.15


                               II. OTHER BUSINESS

     As of this Proxy Statement,  the only business which the Board of Directors
intends to present,  and knows that others will present,  at the Meeting is that
herein  above set forth.  If any other  matter or matters are  properly  brought
before the Meeting,  or any  adjournments  thereof,  it is the  intention of the
persons  named in the  accompanying  form of  proxy  to vote  the  proxy on such
matters in accordance with their judgement.

                           III. SHAREHOLDERS PROPOSALS

     The Annual Meeting of the Company for the year ending  December 31, 2001 is
scheduled to be held in June 2002. In order to have any proposal  presented by a
shareholder at such meeting  included in the Company's  proxy statement and form
of proxy  relating to the meeting,  the proposal must be received by the Company
no later than December 15, 2001.

                                      By Order of the Board of Directors,


                                      VIRGINIA FITZPATRICK, Secretary


Dated: May 11, 2001
New York, New York


--------------------------------------------------------------------------------
A COPY OF THE COMPANY'S ANNUAL REPORT OR FORM 10-K FOR THE YEAR ENDED DECEMBER
31, 2000 MAY BE OBTAINED BY SHAREHOLDERS SOLICITED HEREBY (WITHOUT CHARGE) UPON
WRITTEN REQUEST TO FATIMA S. BAHA, INVESTOR RELATIONS, DAXOR CORPORATION, 350
FIFTH AVENUE, SUITE 7120, NEW YORK, NEW YORK, 10118.
--------------------------------------------------------------------------------


                                       7
</TEXT>
</DOCUMENT>
